Voluntis (Paris:VTX) (Euronext Paris:VTX)(Mnemo:VTX) (ISIN:FR0004183960) on Wednesday announced its plans to enhance patient care coordination in immunology via innovative digital therapeutic software in collaboration with the research-based global biopharmaceutical company AbbVie.
Under the partnership, AbbVie will leverage Voluntis' proven Theraxium technology to make this new solution available to patients and providers in the US.
Through the Theraxium technology platform, Voluntis designs and operates multiple digital therapeutics, including Insulia and Diabeo in diabetes as well as eCO and ZEMY in oncology.
Based out of Boston and Paris, France, Voluntis creates digital therapeutics that empower people suffering from chronic conditions to self-manage ther treatment every day, thus improving real-world outcomes and is a founding member of the Digital Therapeutics Alliance.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes